Dr. Shi of EdgeTech Law: Genome Sequencing Could Soon Enter Mainstream
In Part III of our interview with Dr. Qin Shi of Edgetech Law we visit the concept of human genome sequencing as a mainstream commodity.
cancer
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Dr. Shi of EdgeTech Law: Emerging Opportunities in Life Sciences, Abroad
In Part II of our special interview series, Dr. Qin Shi of Edgetech Law discusses the emerging areas of significant unmet need in life science, and what investment opportunities may arise.
Biovest CEO and Sr. Vice President Discuss Global Marketing of BiovaxID
Biovest International, Inc. (OTCQB: BVTI) announced that Biovest is seeking marketing approval in Canada for BiovaxID®, its personalized cancer vaccine for the treatment of follicular non-Hodgkin’s lymphoma.
Complete Genomics Well Positioned to Move from Research to Clinical in Genome Sequencing
OneMedRadio recently conducted an interview with Dr. Clifford A. Reid, the company’s President and Chief Executive Officer.
Epigenomics Enrolls First Participant in its FIT Comparative Study with Epi proColon®
OneMedRadio interviewed Thomas Taapken, CFO of Epigenomics, a Berlin based molecular diagnostics company for the early detection of cancer.
Advaxis Receives Best Therapeutic Vaccine Award
The 5th Annual Vaccine Industry Excellence Awards has named Advaxis as the Best Therapeutic Vaccine for the company’s ADVX-HPV construct.
Dr. Cynthia Haines, Health Information Guru: How Patients Can Combat a Broken Healthcare System
In this unprecedented age of technology and communication, many wonder why the healthcare industry has traditionally not been on the cutting edge.
Patent Infringement Special Report: Part II, History and Precedent
Part two of our Special Report highlight an important case that may significantly affect the patent infringement landscape. Shares of Myriad Genetics fell 10 percent in the wake of the Mayo ruling.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.